ES2552512T3 - Aminas C-28 de derivados de ácido betulínico modificado en C-3 como inhibidores de la maduracion del virus de inmunodeficiencia humana - Google Patents

Aminas C-28 de derivados de ácido betulínico modificado en C-3 como inhibidores de la maduracion del virus de inmunodeficiencia humana Download PDF

Info

Publication number
ES2552512T3
ES2552512T3 ES12702946.0T ES12702946T ES2552512T3 ES 2552512 T3 ES2552512 T3 ES 2552512T3 ES 12702946 T ES12702946 T ES 12702946T ES 2552512 T3 ES2552512 T3 ES 2552512T3
Authority
ES
Spain
Prior art keywords
alkyl
group
formula
substituted
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES12702946.0T
Other languages
English (en)
Spanish (es)
Inventor
Alicia Regueiro-Ren
Jacob Swidorski
Sing-Yuen Sit
Yan Chen
Jie Chen
Nicholas A. Meanwell
Zheng Liu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Application granted granted Critical
Publication of ES2552512T3 publication Critical patent/ES2552512T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ES12702946.0T 2011-01-31 2012-01-27 Aminas C-28 de derivados de ácido betulínico modificado en C-3 como inhibidores de la maduracion del virus de inmunodeficiencia humana Active ES2552512T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161437870P 2011-01-31 2011-01-31
US201161437870P 2011-01-31
PCT/US2012/022847 WO2012106188A1 (en) 2011-01-31 2012-01-27 C-28 amines of c-3 modified betulinic acid derivatives as hiv maturation inhibitors

Publications (1)

Publication Number Publication Date
ES2552512T3 true ES2552512T3 (es) 2015-11-30

Family

ID=45567146

Family Applications (1)

Application Number Title Priority Date Filing Date
ES12702946.0T Active ES2552512T3 (es) 2011-01-31 2012-01-27 Aminas C-28 de derivados de ácido betulínico modificado en C-3 como inhibidores de la maduracion del virus de inmunodeficiencia humana

Country Status (19)

Country Link
US (1) US8748415B2 (enExample)
EP (1) EP2670764B1 (enExample)
JP (1) JP6000283B2 (enExample)
CN (1) CN103339141B (enExample)
BR (1) BR112014010105A2 (enExample)
CA (1) CA2826257A1 (enExample)
CY (1) CY1116989T1 (enExample)
DK (1) DK2670764T3 (enExample)
EA (1) EA023578B1 (enExample)
ES (1) ES2552512T3 (enExample)
HR (1) HRP20151212T1 (enExample)
HU (1) HUE026371T2 (enExample)
MX (1) MX2013008359A (enExample)
PL (1) PL2670764T3 (enExample)
PT (1) PT2670764E (enExample)
RS (1) RS54352B1 (enExample)
SI (1) SI2670764T1 (enExample)
SM (1) SMT201500303B (enExample)
WO (1) WO2012106188A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2758419B8 (en) 2011-09-21 2017-04-19 VIIV Healthcare UK (No.5) Limited Novel betulinic acid derivatives with antiviral activity
US8906889B2 (en) 2012-02-15 2014-12-09 Bristol-Myers Squibb Company C-3 cycloalkenyl triterpenoids with HIV maturation inhibitory activity
US8889854B2 (en) * 2012-05-07 2014-11-18 Bristol-Myers Squibb Company C-17 bicyclic amines of triterpenoids with HIV maturation inhibitory activity
RU2519133C1 (ru) * 2012-11-09 2014-06-10 Леонид Леонидович Клопотенко Мазь, содержащая инкапсулированную тритерпеновую кислоту или ее производные
RU2516952C1 (ru) * 2012-11-09 2014-05-20 Леонид Леонидович Клопотенко Фармацевтическая композиция, содержащая инкапсулированную тритерпеновую кислоту или ее производные
CN103214543B (zh) * 2012-12-25 2015-09-02 中国人民解放军海军医学研究所 新山楂酸衍生物、其制备方法及其在抗肿瘤药物中的应用
EA027371B1 (ru) * 2013-02-06 2017-07-31 Бристол-Майерс Сквибб Компани C-19 модифицированные тритерпеноиды с ингибиторной активностью созревания вич
BR112015019590A2 (pt) * 2013-02-25 2017-07-18 Bristol Myers Squibb Co derivados de ácido betulínico modificado com c-3 alquila e alquenila úteis no tratamento de hiv
MX374543B (es) 2014-04-11 2025-03-06 Viiv Healthcare Uk No 4 Ltd Triterpenoides con actividad inhibidora de la maduración del virus de inmunodeficiencia humana, sustituidos en la posición 3 con un anillo no aromático que lleva un sustituyente haloalquilo.
US9920090B2 (en) * 2014-06-19 2018-03-20 VIIV Healthcare UK (No.5) Limited Betulinic acid derivatives with HIV maturation inhibitory activity
RU2017118576A (ru) 2014-11-14 2018-12-14 ВАЙВ ХЕЛТКЕР ЮКей (N5) ЛИМИТЕД C-17-арил-замещённые аналоги бетулиновой кислоты
AU2015346303B2 (en) * 2014-11-14 2018-03-15 VIIV Healthcare UK (No.5) Limited Oxolupene derivatives
US9914747B2 (en) 2014-11-14 2018-03-13 VIIV Healthcare UK (No.5) Limited Extended betulinic acid analogs
JP2018512433A (ja) * 2015-04-14 2018-05-17 ヴィーブ ヘルスケア ユーケー(ナンバー4)リミテッド Hiv成熟阻害剤の製造方法
KR20180028534A (ko) 2015-07-28 2018-03-16 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 Hiv 감염을 예방하거나 치료하기 위한 베투인 유도체
RU2018105352A (ru) 2015-07-28 2019-08-29 ГлаксоСмитКлайн Интеллекчуал Проперти (N2) Лимитед Производные бетулина для предупреждения или лечения ВИЧ-инфекций
RU2018112958A (ru) 2015-09-24 2019-10-28 ГлаксоСмитКлайн Интеллекчуал Проперти (N2) Лимитед Соединения с ингибирующей созревание ВИЧ активностью
CN108699103A (zh) 2016-01-20 2018-10-23 葛兰素史克知识产权第二有限公司 具有hiv成熟抑制活性的羽扇烷类的胺衍生物
AR107512A1 (es) 2016-02-04 2018-05-09 VIIV HEALTHCARE UK Nº 5 LTD Triterpenoides modificados en c-3 y c-17 como inhibidores del vih-1
EP3478703A1 (en) * 2016-06-30 2019-05-08 ViiV Healthcare UK (No.5) Limited Triterpenoid inhibitors of human immunodeficiency virus replication
EP3681507B8 (en) * 2017-09-13 2024-03-13 Emmyon, Inc. Ursolic acid morpholine and diethanolamine salts
CN111417384A (zh) 2017-09-14 2020-07-14 菲尼克斯生物技术公司 用于治疗神经系统病况的方法和改进的神经保护性组合物
CA3075729A1 (en) 2017-09-14 2019-03-21 Phoenix Biotechnology, Inc. Use of oleandrin to treatn viral infection
JP7436385B2 (ja) 2018-04-24 2024-02-21 ヴィーブ ヘルスケア ユーケー(ナンバー5)リミテッド Hiv成熟阻害活性を有する化合物
PL237998B1 (pl) 2018-05-28 2021-06-28 Narodowy Inst Lekow Fosfonowe pochodne kwasu 3-karboksyacylobetulinowego, sposób ich otrzymywania oraz ich zastosowanie
US10343997B1 (en) 2018-12-04 2019-07-09 King Saud University Ursolic acid derivatives
KR20220151038A (ko) 2020-03-31 2022-11-11 피닉스 바이오테크놀러지 인코포레이티드. 코로나바이러스 감염 예방를 위한 조성물
EP4295854A3 (en) 2020-03-31 2024-04-03 Phoenix Biotechnology, Inc. Method and compositions for treating coronavirus infection

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5413999A (en) 1991-11-08 1995-05-09 Merck & Co., Inc. HIV protease inhibitors useful for the treatment of AIDS
US5869535A (en) 1995-03-21 1999-02-09 The Board Of Trustees Of The University Of Illinois Method and composition for selectively inhibiting melanoma
US5962527A (en) 1995-03-21 1999-10-05 The Board Of Trustees Of The University Of Illinois Method and composition for treating cancers
US5679828A (en) 1995-06-05 1997-10-21 Biotech Research Labs, Inc. Betulinic acid and dihydrobetulinic acid derivatives and uses therefor
US20040110785A1 (en) 2001-02-02 2004-06-10 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
US7365221B2 (en) 2002-09-26 2008-04-29 Panacos Pharmaceuticals, Inc. Monoacylated betulin and dihydrobetulin derivatives, preparation thereof and use thereof
US20050014730A1 (en) 2003-04-02 2005-01-20 Carlson Robert M. Anti-fungal formulation of triterpene and essential oil
US7745625B2 (en) 2004-03-15 2010-06-29 Bristol-Myers Squibb Company Prodrugs of piperazine and substituted piperidine antiviral agents
EP1730163A4 (en) 2004-03-17 2009-12-30 Panacos Pharmaceuticals Inc Pharmaceutical salts of 3-O- (3,3-dimethylsuccinyl) betulinic acid
TW200628161A (en) 2004-11-12 2006-08-16 Panacos Pharmaceuticals Inc Novel betulin derivatives, preparation thereof and use thereof
CN101142227A (zh) * 2004-11-12 2008-03-12 帕纳克斯医药公司 新颖的桦木醇衍生物、其制备和其用途
WO2008127364A2 (en) 2006-10-13 2008-10-23 Myriad Genetics, Inc. Antiviral compounds and use thereof
WO2008115281A2 (en) 2006-10-16 2008-09-25 Myriad Genetics, Inc. Compounds for treating viral infections
WO2012106190A1 (en) * 2011-01-31 2012-08-09 Bristol-Myers Squibb Company C-17 and c-3 modified triterpenoids with hiv maturation inhibitory activity
JP2011511812A (ja) 2008-02-14 2011-04-14 バイロケム ファーマ インコーポレイテッド 新規17βルパン誘導体
US9067966B2 (en) 2009-07-14 2015-06-30 Hetero Research Foundation, Hetero Drugs Ltd. Lupeol-type triterpene derivatives as antivirals
BR112012030810A2 (pt) * 2010-06-04 2019-09-24 Bristol-Myers Squibb Company "c-28 amidas de derivados de ácido c-3 betulínico modificados como inibidores de maturação de hiv"
CA2801487C (en) * 2010-06-04 2017-12-05 Bristol-Myers Squibb Company Modified c-3 betulinic acid derivatives as hiv maturation inhibitors

Also Published As

Publication number Publication date
BR112014010105A2 (pt) 2017-06-13
JP6000283B2 (ja) 2016-09-28
SMT201500303B (it) 2016-01-08
HRP20151212T1 (hr) 2015-12-04
CA2826257A1 (en) 2012-08-09
EA023578B1 (ru) 2016-06-30
SI2670764T1 (sl) 2016-03-31
US20130029954A1 (en) 2013-01-31
HUE026371T2 (en) 2016-05-30
CY1116989T1 (el) 2017-04-05
PL2670764T3 (pl) 2016-02-29
EA201391098A1 (ru) 2013-12-30
MX2013008359A (es) 2013-08-27
PT2670764E (pt) 2015-11-20
JP2014507422A (ja) 2014-03-27
EP2670764A1 (en) 2013-12-11
CN103339141A (zh) 2013-10-02
RS54352B1 (sr) 2016-02-29
DK2670764T3 (en) 2015-12-07
US8748415B2 (en) 2014-06-10
CN103339141B (zh) 2016-08-24
WO2012106188A1 (en) 2012-08-09
EP2670764B1 (en) 2015-09-02

Similar Documents

Publication Publication Date Title
HRP20151212T1 (hr) C-28 AMINI C-3 MODIFICIRANIH DERIVATA BETULINSKE KISELINE KAO INHIBITORI SAZRIJEVANJA HIV-a P
CO6571891A2 (es) Inhibidores del virus de la hepatitis c.
ZA202107015B (en) Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use
IL274901B2 (en) Substituted nucleosides, nucleotides and analogs thereof
MX2021005850A (es) Heterociclos funcionalizados como agentes antivirales.
CR20220109A (es) Profármacos antivirales y formulaciones de los mismos
DOP2019000140A (es) Compuestos de heterociclo tetracíclicos útiles como inhibidores de la integrasa del vih
NI201200139A (es) Compuestos de sililo tricíclicos fusionados y métodos de uso de los mismos para el tratamiento de enfermedades virales.
AR094876A1 (es) Derivados de ácido betulínico modificados con alquilo c-3 y alquenilo
CY1117113T1 (el) Αναστολεις πρωτεασης σερινης hcv λαμβανομενοι απο μακροκυκλικη προλινη
CO6361922A2 (es) Inhibidores del virus de la hepatitis c
NZ612159A (en) Macrocyclic inhibitors of flaviviridae viruses
JP2014507422A5 (enExample)
AR081691A1 (es) Derivados de tiofeno, metodos para su preparacion y su uso en el tratamiento o la prevencion de infecciones por flavivirus
AR081638A1 (es) Amidas c-28 de derivados del acido betulinico c-3 modificados como inhibidores de la maduracion del vih
ECSP14005678A (es) Composiciones y métodos para tratar el virus de la hepatitis c
NZ599133A (en) Hcv protease inhibitors
DOP2013000238A (es) Derivados de nucleosidos 2'-sustituidos y metodos de uso de los mismos para el tratamiento de enfermedades virales
EA202090514A1 (ru) Противовирусное средство против гепатита в
CO6430431A2 (es) Inhibidores del virus de la hepatitis c
EA201200890A1 (ru) Комбинированная терапия hcv
CL2021002390A1 (es) Derivados de pirimidona de anillo fusionado para su uso en el tratamiento de la infección por vhb (virus hepatitis b) o de enfermedades inducidas por el vhb.
UY38383A (es) Heterociclos funcionalizados como agentes antivirales
AR080185A1 (es) Derivados de acido boronico y benzofurano, composiciones farmaceuticas que los contienen,y uso de los mismos en el tratamiento y/o prevencion de infecciones virales, en particular por el virus de hepatitis c(hcv).
MX384729B (es) Compuestos heterocíclicos tricíclicos útiles como inhibidores de la integrasa del virus de inmunodeficiencia humana (vih).